Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by Van ECK Associates Corp

Van ECK Associates Corp grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 6.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,175,236 shares of the company’s stock after purchasing an additional 134,407 shares during the quarter. Van ECK Associates Corp owned 0.07% of Takeda Pharmaceutical worth $30,149,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of TAK. Mondrian Investment Partners LTD raised its position in shares of Takeda Pharmaceutical by 47.9% during the 1st quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after purchasing an additional 3,912,569 shares during the period. Millennium Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after acquiring an additional 2,023,707 shares during the period. Cowen AND Company LLC bought a new position in shares of Takeda Pharmaceutical during the second quarter worth about $6,866,000. Manning & Napier Advisors LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter valued at about $4,098,000. Finally, Hantz Financial Services Inc. bought a new position in Takeda Pharmaceutical in the 2nd quarter worth about $2,843,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.6 %

Shares of Takeda Pharmaceutical stock opened at $14.05 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The business’s fifty day moving average price is $14.46 and its two-hundred day moving average price is $13.80. The company has a market capitalization of $44.71 billion, a P/E ratio of 24.22, a PEG ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.